Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6

ObjectiveTo evaluate whether plasma concentrations of procalcitonin (PCT), interleukin-6 (IL-6), protein complement 3a (C3a), leukocyte elastase (elastase), and the C-reactive protein (CRP) determined directly after the clinical onset of sepsis or systemic inflammatory response syndrome (SIRS) discriminate between patients suffering from sepsis or SIRS and predict the outcome of these patients. DesignProspective study. SettingMedical intensive care unit at a university hospital. PatientsTwenty-two patients with sepsis and 11 patients with SIRS. Measurements and Main ResultsThe plasma concentrations of PCT, C3a, and IL-6 obtained ≤8 hrs after clinical onset of sepsis or SIRS but not those of elastase or CRP were significantly higher in septic patients ( PCTmedian, 16.8 ng/mL, range, 0.9–351.2 ng/mL, p = .003; C3a: median, 807 ng/mL, range, 422-4788 ng/mL, p < .001; IL-6: median, 382 pg/mL, range, 5–1004 pg/mL, p = .009, all Mann-Whitney rank sum test) compared with patients suffering from SIRS ( PCTmedian, 3.0 ng/mL, range, 0.7–29.5 ng/mL; C3a: median, 409 ng/mL, range, 279–566 ng/mL; IL-6: median, 98 pg/mL, range, 23–586 pg/mL). The power of PCT, C3a, and IL-6 to discriminate between septic and SIRS patients was determined in a receiver operating characteristic analysis. C3a was the best variable to differentiate between both populations with a maximal sensitivity of 86% and a specificity of 80%. An even better discrimination (i.e., a maximal sensitivity of 91% and a specificity of 80%) was achieved when PCT and C3a were combined in a “sepsis score.” C3a concentrations also helped to predict the outcome of patients. Based on the sepsis score, a logistic regression model was developed that allows a convenient and reliable determination of the probability of an individual patient to suffer from sepsis or SIRS. ConclusionsOur data show that the determination of PCT, IL-6, and C3a is more reliable to differentiate between septic and SIRS patients than the variables CRP and elastase, routinely used at the intensive care unit. The determination of PCT and C3a plasma concentrations appears to be helpful for an early assessment of septic and SIRS patients in intensive care.

[1]  G. Steinbach,et al.  Procalcitonin--a new indicator for bacterial infections. , 2009, Experimental and clinical endocrinology & diabetes.

[2]  W. Konertz,et al.  Hyperprocalcitonemia in Patients with Noninfectious SIRS and Pulmonary Dysfunction Associated with Cardiopulmonary Bypass , 1998, Anesthesiology.

[3]  M. Oberhoffer,et al.  Procalcitonin Ein neuer diagnostischer Parameter bei schweren Infektionen und Sepsis , 1998, Der Anaesthesist.

[4]  J. White,et al.  Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. , 1998, Critical care medicine.

[5]  Ronald McCarthy,et al.  Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis , 1998, Nature Medicine.

[6]  T. Hugli,et al.  Characterization of Complement Anaphylatoxins and Their Biological Responses , 1998 .

[7]  J. Köhl,et al.  Circulating complement proteins in multiple trauma patients--correlation with injury severity, development of sepsis, and outcome. , 1997, Critical care medicine.

[8]  G. Steinbach,et al.  The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis , 1997, Gut.

[9]  T. Staudinger,et al.  Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. , 1997, American journal of respiratory and critical care medicine.

[10]  J. Bland,et al.  Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. , 1996, Critical care medicine.

[11]  K. Becker,et al.  Pneumonitis-associated hyperprocalcitoninemia. , 1996, The American journal of the medical sciences.

[12]  R. Wenzel,et al.  Current understanding of sepsis. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  T. Welte,et al.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome , 1996, Clinical and diagnostic laboratory immunology.

[14]  C. Hack,et al.  Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. , 1995, Blood.

[15]  R. Goris,et al.  Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma. , 1995, Critical care medicine.

[16]  A. Whitehead,et al.  The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.

[17]  J. Köhl,et al.  Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures. , 1993, Journal of immunological methods.

[18]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[19]  I. L. Cohen.  Guidelines for the use of innovative therapies in sepsis. , 1993, Critical care medicine.

[20]  M. Assicot,et al.  High serum procalcitonin concentrations in patients with sepsis and infection , 1993, The Lancet.

[21]  S. Vesconi,et al.  Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Correlation with severity of disease. , 1992, Archives of surgery.

[22]  C. Hack,et al.  Interleukin-8 in sepsis: relation to shock and inflammatory mediators , 1992, Infection and immunity.

[23]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[24]  R. Bone,et al.  Gram-negative sepsis. Background, clinical features, and intervention. , 1991, Chest.

[25]  L. G. Thijs,et al.  Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .

[26]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[27]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[28]  T. Hugli,et al.  Anaphylatoxin generation in multisystem organ failure. , 1984, The Journal of trauma.

[29]  Jean-Guy Cyr,et al.  Principles and Practice of Infectious Diseases , 1980 .

[30]  J. Carrizosa.  Gram-negative sepsis. , 1976, Journal of the American Medical Women's Association.

[31]  K. Reinhart,et al.  [Procalcitonin. A new diagnostic parameter for severe infections and sepsis]. , 1998, Der Anaesthesist.

[32]  C. Hack,et al.  Complement activation in patients with sepsis is in part mediated by C-reactive protein. , 1998, The Journal of infectious diseases.

[33]  J. Köhl,et al.  Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. , 1995, Journal of immunological methods.

[34]  C. Hack,et al.  Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. , 1989, The American journal of medicine.